Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of 13-Cis Retinoic Acid, Alpha Interferon, Taxotere, and Estramustine (R.I.T.E.) for the Treatment of Hormone Refractory Prostate Cancer

NCT00176527 is registered in ClinicalTrials.gov with University of Medicine and Dentistry of New Jersey as lead sponsor.

NCT NCT00176527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00176527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of 13-Cis Retinoic Acid, Alpha Interferon, Taxotere, and Estramustine (R.I.T.E.) for the Treatment of Hormone Refractory Prostate Cancer
Lead sponsor
University of Medicine and Dentistry of New Jersey
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2002
Completion date
August 31, 2007
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer